Kennedy Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Kennedy Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208K	Buy	97,726 +1,864	+2%	+$3.2K	﹤0.01%	542
2026 Q1	$162K	Sell	95,862 -1,159,976	-92%	-$5.08M	﹤0.01%	535
2025 Q4	$6.51M	Buy	1,255,838 +143,625	+13%	+$738K	0.14%	243
2025 Q3	$5.81M	Buy	1,112,213 +425,245	+62%	+$2.22M	0.13%	268
2025 Q2	$2.63M	Sell	686,968 -546,446	-44%	-$1.41M	0.06%	398
2025 Q1	$7.09M	Sell	1,233,414 -235,105	-16%	-$1.39M	0.17%	212
2024 Q4	$7.33M	Sell	1,468,519 -412,559	-22%	-$2.12M	0.16%	218
2024 Q3	$10.1M	Buy	1,881,078 +281,405	+18%	+$1.34M	0.22%	138
2024 Q2	$5.29M	Buy	1,599,673 +281,518	+21%	+$1.1M	0.11%	306
2024 Q1	$4.31M	Buy	1,318,155 +42,009	+3%	+$138K	0.09%	355
2023 Q4	$4.48M	Buy	+1,276,146	New	+$3.94M	0.1%	325

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Kennedy Capital Management's ALDX Position: Q2 2026 in Review

Kennedy Capital Management increased its Aldeyra Therapeutics (ALDX) stake by 1.9% in Q2 2026, buying an estimated $3.2K and bringing the position to 97,726 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #542.

Kennedy Capital Management first reported a position in ALDX in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.1M in Q3 2024. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Kennedy Capital Management held 97,726 shares of Aldeyra Therapeutics worth $208K as of Q2 2026.
Kennedy Capital Management bought 1,864 Aldeyra Therapeutics shares in Q2 2026, an estimated $3.2K.
Aldeyra Therapeutics made up ﹤0.01% of Kennedy Capital Management's portfolio in Q2 2026, its #542 holding.
Kennedy Capital Management first reported a position in Aldeyra Therapeutics in Q4 2023 and has held it in 11 quarters since.
Kennedy Capital Management's Aldeyra Therapeutics position peaked at $10.1M in Q3 2024.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.